Press Release

Elixirgen Therapeutics is currently enrolling patients in its Phase 1/2 trial evaluating EXG-34217 in patients with telomere biology disorders at Cincinnati Children’s Hospital Medical Center BALTIMORE, September 25, 2024 – Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its mRNA platforms, today announced that the U.S. […]

Bobcat mRNATM technology is a novel linear mRNA platform able to encode large proteins Data showed restoration of muscular function in DMD mouse model BALTIMORE, March 4, 2024 – Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its mRNA platforms, today presented preclinical data on its

No safety concerns were observed with EXG‑5003 administration The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines. The Company is exploring the use of the c-srRNA platform for the development of vaccines, cell therapies and immunotherapies for several indications BALTIMORE, October 16, 2023 – Elixirgen Therapeutics,

BALTIMORE, January 26, 2023 – Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced that it has entered a memorandum of understanding with Hitachi Global Life Solutions, Inc. (Hitachi GLS) for the development of Micro GMP suites to facilitate

BALTIMORE, Jan. 04, 2023 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced that members of the management team will be attending the Biotech Showcase Conference taking place January 9-11, 2023 in San Francisco, California. Akihiro Ko, chief

BALTIMORE, Dec. 21, 2022 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced the appointment of Jeffrey L. Cleland, Ph.D., to the Board of Directors to support the advancement of its technology in developing therapies for a broad

Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting Treatment with EXG-34217 increased the telomere length of CD34+ cells by 1.24-fold ex vivo Telomere flow-FISH study suggests the potential emergence of a cell population with longer telomeres in vivo No acute or

BALTIMORE, November 7, 2022 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced an oral presentation of new data showing successful ex vivo telomere elongation with lead asset, EXG-34217 (autologous CD34+ hematopoietic stem cells that have been treated

BALTIMORE, September 7, 2022 — Elixirgen Therapeutics, Inc., a Baltimore-based, clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies using its controllable srRNA platform, announced today that it has posted a manuscript titled “Controllable self-replicating RNA vaccine delivered intradermally elicits cellular immunity” on the bioRxiv.org preprint server. The link to the preprint

BALTIMORE, March 7, 2022 — Elixirgen Therapeutics, Inc., a Baltimore-based platform biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, announced today that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The partnership will leverage Elixirgen Therapeutics’ proprietary ZSCAN4 therapy platform to